General Journal Policies
Conflicts of Interest
Conflict of Interest Statement for JAMA and Archives Journals Editorial Staff
Editorial Governance for JAMA
Release of Information to the Public and Embargo Policy

Manuscript Submission Policies
Authorship/Group Authorship
Clinical Trial Registration
Evaluation of Manuscripts
Expedited Review/JAMA-EXPRESS
Depositing Research Articles With Funding Organizations
Reporting Race and Ethnicity

• Update on JAMA's Conflict of Interest Policy. JAMA. 2006;296;220-221.
  Describes new requirement for authors to include potential conflicts of interest in the acknowledgment section of submitted manuscripts.
• Reporting Conflicts of Interest, Financial Aspects of Research, and Role of Sponsors in Funded Studies. JAMA. 2005;294:110-111.
  Defines requirements for reporting financial conflicts of interest, contributions, and role of the funding organization(s); access to data; requirements for independent statistical analysis for industry-funded research; and reporting clinical trials.
• Reporting Financial Conflicts of Interest and Relationships Between Investigators and Research Sponsors. JAMA. 2001;286:89-91.
  Defines conflicts of interest, and provides JAMA policies on reporting financial conflicts of interest and relationships between investigators and research sponsors, and policies on financial disclosures by JAMA Editors, Editorial Board members, and peer reviewers.
• Sponsorship, Authorship, and Accountability. JAMA. 2001;286:1232-1234.
  Describes policies on sponsorship, authorship, and accountability from the International Committee of Medical Journal Editors.
• See also Editorial Policies for Authors in Instructions for Authors.

• Editorial Governance for JAMA. JAMA. 1999;281:2240-2242.
• Update of the Editorial Governance Plan for JAMA. JAMA. 2004;291:109.
• These editorials explicate JAMA’s governance and relationship with the American Medical Association.

• THE JOURNAL's Policy Regarding Release of Information to the Public. JAMA. 2001;286:89-91.
  Defines which forms of dissemination are considered acceptable and are not considered prior publication for purposes of submission to JAMA, and defines and discusses JAMA’s embargo policy.
• Additional information about JAMA’s embargo policy may be found at:
  The Importance of the Journal Embargo. JAMA. 2002;288:748-750.

• The Contributions of Authors. JAMA. 2000;284:89-91.
  Introduces requirements for author contributions and explains types of contributions.
• Authorship for Research Groups. JAMA. 2002;288:3166-3168.
  Provides JAMA’s policies on group authorship.
• See also Editorial Policies for Authors in Instructions for Authors.

• Clinical Trial Registration: A Statement From the International Committee of Medical Journal Editors. JAMA. 2004;292:1363-1364.
• Is This Clinical Trial Fully Registered?: A Statement From the International Committee of Medical Journal Editors. JAMA. 2005;293:2927-2929.
• These statements from the ICMJE define which clinical trials must be registered, when, and where, for consideration for publication in JAMA.

• Information for JAMA Authors–2004. JAMA. 2004;291:107-108.
  Provides specific information about many of the criteria JAMA uses to assess manuscripts submitted for consideration for possible publication.

• JAMA-EXPRESS: Rapid Peer Review and Publication. JAMA. 1999;281:1754-1755.
  Provides criteria for expedited consideration of clinical trials and other studies of major clinical and/or public health importance under JAMA-EXPRESS.

• Measuring Race and Ethnicity: Why and How? JAMA. 2004;292:1612-1614.
  Explains how race and ethnicity should be reported in JAMA.